New drug trial aims to stop aggressive cancer from coming back
NCT ID NCT07279532
Summary
This study is testing if a drug called surufatinib can help prevent cancer from returning after surgery in patients with high-risk neuroendocrine tumors. It will enroll about 35 patients whose cancer is classified as Stage III or has other high-risk features. The main goal is to see if the drug extends the time patients live without their cancer coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASMS (TUMOURS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.